Cardiovascular Disease

>

Latest News

Plozasiran, an Investigational RNAi Therapy, Reduces Triglyceride Levels in Adults with Mixed Hyperlipidemia / image credit Christie M Ballantyne, MD, courtesy of Baylor College of Medicine
Plozasiran, an Investigational RNAi Therapy, Reduces Triglyceride Levels in Adults with Mixed Hyperlipidemia

May 28th 2024

Plozasiran, in the phase 2b MUIR trial, significantly reduced triglyceride and triglyceride rich lipoprotein levels through targeted action against APOC3.

New Study Shows Men with Diabetes Have Higher Risk of Disease-related Complications than Women
New Study Shows Men with Diabetes Have Higher Risk of Disease-related Complications than Women

May 17th 2024

Cardiovascular-Kidney-Metabolic Syndrome in the US: Daily Dose / image credit: ©New Africa/AdobeStock
Cardiovascular-Kidney-Metabolic Syndrome in the US: Daily Dose

May 16th 2024

Semaglutide Supports Long-Term Weight Loss, Reduces CV Risk Across BMI Subgroups
Semaglutide Supports Long-Term Weight Loss, Reduces CV Risk Across BMI Subgroups

May 15th 2024

May Issue of Patient Care Online Digital Edition is Now Live
May Issue of Patient Care Online Digital Edition is Now Live

May 14th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.